- Home
- CTOR vs CKPT Comparison
CTOR vs CKPT Comparison
Compare CTOR & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- CKPT
- Stock Information
- Founded
- CTOR 2021
- CKPT 2014
- Country
- CTOR United States
- CKPT United States
- Employees
- CTOR N/A
- CKPT N/A
- Industry
- CTOR
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- CKPT Health Care
- Exchange
- CTOR NYSE
- CKPT Nasdaq
- Market Cap
- CTOR 126.2M
- CKPT 102.0M
- IPO Year
- CTOR N/A
- CKPT 2017
- Fundamental
- Price
- CTOR $1.55
- CKPT $2.46
- Analyst Decision
- CTOR Strong Buy
- CKPT Strong Buy
- Analyst Count
- CTOR 1
- CKPT 2
- Target Price
- CTOR $6.00
- CKPT $12.00
- AVG Volume (30 Days)
- CTOR 87.9K
- CKPT 307.3K
- Earning Date
- CTOR 08-12-2024
- CKPT 11-11-2024
- Dividend Yield
- CTOR N/A
- CKPT N/A
- EPS Growth
- CTOR N/A
- CKPT N/A
- EPS
- CTOR N/A
- CKPT N/A
- Revenue
- CTOR N/A
- CKPT $78,000.00
- Revenue This Year
- CTOR N/A
- CKPT N/A
- Revenue Next Year
- CTOR N/A
- CKPT $100,731.91
- P/E Ratio
- CTOR N/A
- CKPT N/A
- Revenue Growth
- CTOR N/A
- CKPT N/A
- 52 Week Low
- CTOR $1.53
- CKPT $1.30
- 52 Week High
- CTOR $49.00
- CKPT $3.62
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- CKPT 61.08
- Support Level
- CTOR N/A
- CKPT $2.06
- Resistance Level
- CTOR N/A
- CKPT $2.58
- Average True Range (ATR)
- CTOR 0.00
- CKPT 0.13
- MACD
- CTOR 0.00
- CKPT 0.03
- Stochastic Oscillator
- CTOR 0.00
- CKPT 76.92
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.